FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
4D Molecular Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$12.29+0.15 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $863.64M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
4D Molecular Therapeutics has not reported a dividend
No dividend per share appears in 4D Molecular Therapeutics's annual filings since fiscal 2018.